AMAG Pharma (AMAG), Takeda Get Marketing Approval for Feraheme in Canada

AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) and Takeda Canada, Inc. today announced that Health Canada granted marketing approval on December 8, 2011 for Feraheme® (ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Under an agreement with AMAG, Takeda has an exclusive license to market Feraheme for all therapeutic applications in Canada. Upon the first commercial sale of Feraheme in Canada, AMAG will receive a milestone payment of $3 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Lazard Global Total Return fund declares $0.1534 monthly distribution
• Hinge Health signs $86M office lease in San Francisco